Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | GRM5 | P41594 | 6/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021665 | 0.88 | KDM4E (0.61) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL13986853 | 0.86 | KDM4E (0.59) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL9022425 | 0.84 | KDM4E (0.58) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL9024311 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL3415023 | 0.82 | ALDH1A1 (0.53) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL31172969 | 0.81 | GRM5 (0.54) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL995794 | 0.81 | GRM5 (0.54) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL17116615 | 0.81 | KDM4E (0.55) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL31108745 | 0.81 | GRM5 (0.51) | KDM4EALDH1A1HPGDL3MBTL1HTT | |
| SCHEMBL5145719 | 0.81 | GRM5 (0.51) | KDM4EALDH1A1HPGDL3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969925-A | Heteroaryl-triazole compounds | 拜耳公司 | 2023-10-31 | — | — | CN | claimed |
| CN-102209710-A | Pyrrolidines | PFIZER LTD | 2011-10-05 | — | — | CN | claimed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | claimed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | claimed |
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | JNC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| CN-102209710-A | Pyrrolidines | PFIZER LTD | 2011-10-05 | — | — | CN | disclosed |
| EP-2364296-A1 | PYRROLIDINES | Pfizer Limited (GB) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052625-A1 | PYRROLIDINES | PFIZER LIMITED (GB) | 2010-05-14 | — | — | WO | disclosed |
| EP-0929508-B1 | LIQUID CRYSTALLINE (E,E)-BUTADIENE COMPOUNDS AND MIXTURES AND DEVICES CONTAINING SUCH COMPOUNDS | QINETIQ LTD (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-6333082-B1 | USEFUL IN SUPER TWISTED NEMATIC LIQUID CRYSTAL DISPLAYS | QINETIQ LTD (GB) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SLC26A3, SLC9A1, HVCN1 | KDM4E 1450/4885ALDH1A1 1009/4885HPGD 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.